Abstract:The purpose of this paper is to investigate the economic implications of the Japanese healthcare system that is one of the institutional arrangements for rationing medical resources. In addition, based on the view that a healthcare system is a non-market method for resource allocation that takes the place of the market, another purpose of the paper is to highlight the policy issues that will accompany the design of a new healthcare system in Japan. A healthcare system is generally composed of various institutions and regulations that serve to allocate medical resources on both the supply and demand sides of the medical care market1). An analysis of the economic implications of these institutions and regulations will therefore not only shed light on actual resource allocation through the healthcare system, but also contribute to building and maintaining trust relationship between patients and doctors. However, as there are lots of government interventions in the healthcare sector, the impact of the healthcare system on resource allocation is so much complex and complicated. This paper will investigate, both institutionally and theoretically, the economic implications of resource allocation through the two regulations that form the core of Japan’s current healthcare system: the public insurance system and the medical fee system. In Japan and other countries, there are various government interventions on both the supply and demand sides of the medical care market, and several economic reasons have been put forward for such government interventions2). For example, in the healthcare market are many externalities in providing public health and in the treatment and prevention of infectious diseases, and asymmetric information exists between patients and doctors. Furthermore, because an individual cannot predict whether he or she will fall seriously ill, he or she is exposed to the risk of astronomical medical bills. Although private insurance offers a market-based way of alleviating such risk in the private insurance market, the reality is that asymmetric information results in problems such as moral hazard and adverse selection, which prevent the private insurance market from adequately sheltering people from such risk. Another problem with leaving things to the market is that fair access to medical services is hampered. It is for reasons such as these that the government intervenes on both the supply and demand sides of the medical care market.

A commentary on "Guideline for economic evaluation of healthcare technologies in Japan"

The Development of Health Technology Assessment in Asia: Current Status and Future Trends.

National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison

Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries

A Case for the Adoption of Pharmacoeconomic Guidelines in Japan

Development of Health Technology Assessment in Singapore,South Korea and Japan:Overview and Implications for China

An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations

Assessment of the quality of pharmacoeconomic evaluation literature in China

The Health Technology Assessment Environment in Mainland China, Japan, South Korea, and Taiwan—Implications for the Evaluation of Diabetes Mellitus Therapies

[Review of the health technology assessment on surgeries in Japan]

Cost-effectiveness evaluation for pricing medicines and devices: A new value-based price adjustment system in Japan

An Economic Analysis of Institutions and Regulations in the Japanese Healthcare System

The Economic Rationale for Healthcare Reform

Health Technology Assessment and Its Use in Drug Policies in China

Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary

A guideline for economic evaluations of vaccines and immunization programs in China

Incorporating healthcare access and equity in economic evaluations: a scoping review of guidelines

A systematic review of economic evaluation of artificial intelligence-based screening for eye diseases: From possibility to reality

Comparative Study on Global Development Strategies of Artificial Intelligence in Healthcare

OP27 Health Technology Assessment Processes, Characteristics, And Key Differences In High, Middle, And Low-Income Countries Of Asia Pacific Region

Health technology assessment (HTA) and economic evaluation: efficiency or fairness first